TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10624430

Group type: COMPARATOR
Intervention: Standard regimen (g. cyclopentolate 1% stat. and oc. chloramphenicol q.d.s. for 5 days)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Standard regimen followed by additional nightly ointment (Lacrilube) for 2 months
Number of subjects: 74
Study: 8808540

Group type: EXPERIMENTAL
Intervention: Meditation (6 participants)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (non-meditating, 6 participants)
Number of subjects: 12
Study: 2188826

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg daily (n = 68)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Sustained-release nifedipine 20 mg twice daily (n = 68)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Nifedipine group
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Enalapril group
Number of subjects: 136

Group type: COMPARATOR
Intervention: Enalapril vs Nifedipine
Number of subjects: 136
Study: 7198465

Group type: EXPERIMENTAL
Intervention: plafibride (1200 mg/d for 15 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: plafibride
Number of subjects: 90

Group type: COMPARATOR
Intervention: clofibrate
Number of subjects: 90

Group type: COMPARATOR
Intervention: acetylsalicylic acid (ASA)
Number of subjects: 90
Study: 29511062

Group type: EXPERIMENTAL
Intervention: Ranibizumab for 6 months
Number of subjects: 303
Study: 27734563

Group type: EXPERIMENTAL
Intervention: AP-HR (artificial pancreas system connected to a heart rate monitor)
Number of subjects: 18

Group type: COMPARATOR
Intervention: stdAP (unmodified artificial pancreas)
Number of subjects: 18
Study: 25907488

Group type: EXPERIMENTAL
Intervention: Xinkeshu (12 capsules/d) on top of standard therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo on top of standard therapy
Number of subjects: 40
Study: 23868621

Group type: EXPERIMENTAL
Intervention: Nasal polyps (NPs) group (group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (group 2) - patients with septal deviations and concha hypertrophies
Number of subjects: 60
Study: 21836413

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with half-dose verteporfin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 19169191

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (e.g., selective serotonin reuptake inhibitors)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Consensus guidelines on pharmacotherapy for PTSD
Number of subjects: 0
Study: 17878474

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (60 Gy conventional irradiation)
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Wait-and-see
Number of subjects: 1005
Study: 14755505

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC)
Number of subjects: 102
Study: 11090571

Group type: EXPERIMENTAL
Intervention: CC (2 g/kg body wt of CHO in a 25.7% CHO beverage 30 min before and 2 g/kg of CHO in a 6.4% CHO solution throughout SS)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: PC (placebo 30 min before and 2 g/kg body wt of CHO in a 6.4% CHO solution throughout SS)
Number of subjects: 7

Group type: COMPARATOR
Intervention: PP (placebo beverage before and during SS)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: CP (2 g/kg body wt of CHO in a 25.7% CHO beverage 30 min before and placebo throughout SS)
Number of subjects: 7
Study: 9069692

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (40-hour training program)
Number of subjects: 1078

Group type: COMPARATOR
Intervention: Traditional pharmacy services
Number of subjects: 1078
Study: 8417381

Group type: EXPERIMENTAL
Intervention: Radiation therapy with fluorouracil
Number of subjects: 115

Group type: COMPARATOR
Intervention: Radiation therapy without fluorouracil
Number of subjects: 115

Group type: COMPARATOR
Intervention: Smoking cessation (quit more than 1 year before diagnosis)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Smoking cessation (quit less than 12 weeks before diagnosis)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Smoking during radiation therapy
Number of subjects: 115
Study: 3770045

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (2 mg/m2) every 3 weeks for a maximum of eight courses followed by DTIC (250 mg/m2 i.v. daily X 5) and Actinomycin D (1.5 mg/m2 on Day 1)
Number of subjects: 79

Group type: COMPARATOR
Intervention: DTIC (250 mg/m2 i.v. daily X 5) and Actinomycin D (1.5 mg/m2 on Day 1)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum followed by chemotherapy
Number of subjects: 79

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 79
Study: 31314785

Group type: EXPERIMENTAL
Intervention: Concurrent-100% feedback
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Concurrent-50% feedback
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Terminal-100% feedback
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Terminal-50% feedback
Number of subjects: 68
Study: 30154003

Group type: EXPERIMENTAL
Intervention: Surgical endodontic retreatment
Number of subjects: 95

Group type: COMPARATOR
Intervention: Nonsurgical endodontic retreatment
Number of subjects: 95
Study: 26394780

Group type: EXPERIMENTAL
Intervention: L-thyroxine treatment
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 51
Study: 24828081

Group type: EXPERIMENTAL
Intervention: Low emission zone and heavy traffic ban
Number of subjects: 0
Study: 21118409

Group type: EXPERIMENTAL
Intervention: Algorithm I (Empirical CPAP trial)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Algorithm II (Portable sleep monitoring followed by CPAP trial for 3 weeks)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Algorithm I
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Algorithm II
Number of subjects: 248
Study: 20632322

Group type: EXPERIMENTAL
Intervention: Metronidazole 10 per cent ointment, 0.7 g applied perianally three times daily
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Metronidazole 10 per cent ointment
Number of subjects: 74
Study: 18321839

Group type: EXPERIMENTAL
Intervention: Storytelling intervention
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 15978101

Group type: EXPERIMENTAL
Intervention: S18886 1 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: S18886 2.5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: S18886 5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: S18886 10 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: S18886 30 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: S18886
Number of subjects: 30
Study: 12814908

Group type: EXPERIMENTAL
Intervention: Thiamine-enriched beer (10 mg of thiamine)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Normal beer (0 mg of thiamine)
Number of subjects: 49
Study: 10997482

Group type: EXPERIMENTAL
Intervention: SCE (synthetic conjugated estrogens, A) 0.3 mg, 0.625 mg, or 1.25 mg per day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 8827796

Group type: EXPERIMENTAL
Intervention: Hedonic positive affect (exposure to positive dramatic excerpts)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hedonic negative affect (exposure to negative dramatic excerpts)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutral affect (exposure to neutral dramatic excerpts)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no exposure to drama)
Number of subjects: 0
Study: 1448777

Group type: EXPERIMENTAL
Intervention: Low dose epinephrine infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Phenylephrine infusion
Number of subjects: 30
Study: 2868431

Group type: EXPERIMENTAL
Intervention: Nadolol 80 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30629183

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (250 mg intramuscular injections every 2 weeks for 22 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy
Number of subjects: 42
Study: 28388981

Group type: EXPERIMENTAL
Intervention: Mobile type-BHI (mobile application 'Strong bone, Fit body' and group education)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Group education only (experimental group II)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Mobile type-BHI (experimental group I)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study: 25994591

Group type: EXPERIMENTAL
Intervention: Single 30‐min bout of moderate‐intensity exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sedentary control for 30 minutes
Number of subjects: 0
Study: 23170936

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lean control
Number of subjects: 0
Study: 21427372

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (200 mg/d for 5 days, followed by 100 mg on day 6 and 50 mg on day 7)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 150
Study: 19781053

Group type: EXPERIMENTAL
Intervention: 12-week training program
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 110
Study: 16391986

Group type: EXPERIMENTAL
Intervention: Acetazolamide (AZ) plus 0.9% sodium chloride
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sodium bicarbonate (HCO3‐)
Number of subjects: 96
Study: 15262612

Group type: EXPERIMENTAL
Intervention: Preoperative computed tomography (CT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intraoperative epiaortic ultrasound
Number of subjects: 20
Study: 11158489

Group type: EXPERIMENTAL
Intervention: Point-of-care evidence delivery regarding the use and duration of antibiotics for otitis media.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 9164886

Group type: EXPERIMENTAL
Intervention: Signal-averaged electrocardiography in patients with idiopathic dilated cardiomyopathy
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Signal-averaged electrocardiography in relatives with left ventricular enlargement
Number of subjects: 278

Group type: COMPARATOR
Intervention: Normal relatives and healthy controls
Number of subjects: 278
Study: 7700064

Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg
Number of subjects: 20
Study: 2823746

Group type: EXPERIMENTAL
Intervention: Halsted radical mastectomy (RM)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Modified radical mastectomy (MRM)
Number of subjects: 311
Study: 2403603

Group type: EXPERIMENTAL
Intervention: Combination of sulfamethoxazole and trimethoprim (1600/320 mg) plus loperamide hydrochloride (4 mg loading dose, then 2 mg after each loose stool)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole and trimethoprim (800/160 mg orally twice daily)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Loperamide hydrochloride (4 mg loading dose, then 2 mg after each loose stool)
Number of subjects: 227
Study: 31791085

Group type: EXPERIMENTAL
Intervention: 14-gauge core needle biopsy
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: 16-gauge core needle biopsy without coaxial guidance
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: 16-gauge core needle biopsy with coaxial guidance
Number of subjects: 1065

Group type: COMPARATOR
Intervention: 14-gauge core needle biopsy with coaxial guidance
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: 16-gauge core needle biopsy
Number of subjects: 1065
Study: 30677766

Group type: EXPERIMENTAL
Intervention: MP-AzeFlu (137/50 μg AZE/FP per spray)
Number of subjects: 149

Group type: COMPARATOR
Intervention: AZE (137 μg/spray)
Number of subjects: 149
Study: 28287486

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg body mass)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 25462393

Group type: EXPERIMENTAL
Intervention: Short-term psychotherapy (Solution-Focused Therapy, SFT, n=97)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Short-term psychotherapy (Short-Term Psychodynamic Psychotherapy, SPP, n=101)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic psychotherapy (LPP, n=128)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Short-term therapies (SFT and SPP)
Number of subjects: 326
Study: 23963054

Group type: EXPERIMENTAL
Intervention: Oral α‐methylparatyrosine (AMPT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 21227545

Group type: EXPERIMENTAL
Intervention: Good outcome
Number of subjects: 587

Group type: COMPARATOR
Intervention: No outcome provided
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Bad outcome
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Intermediate quality scenarios
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Unambiguously good or bad outcomes
Number of subjects: 587
Study: 19092692

Group type: EXPERIMENTAL
Intervention: AM trial (0645 h)
Number of subjects: 9

Group type: COMPARATOR
Intervention: PM trial (1845 h)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Both trials
Number of subjects: 9
Study: 17050802

Group type: EXPERIMENTAL
Intervention: St John's wort
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Asian ginseng
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ginkgo biloba
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ginger
Number of subjects: 24
Study: 15718064

Group type: EXPERIMENTAL
Intervention: Five-session education program
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard care (control condition)
Number of subjects: 44
Study: 11881749

Group type: EXPERIMENTAL
Intervention: 4 hours of bed rest
Number of subjects: 118

Group type: COMPARATOR
Intervention: 6 hours of bed rest
Number of subjects: 118
Study: 9550506

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for asymptomatic disease
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy with coronary artery bypass surgery
Number of subjects: 463
Study: 7890905

Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg orally daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (identical to colchicine)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 3224534

Group type: EXPERIMENTAL
Intervention: Thiopental (loading dose of 15 mg/kg over 30 min followed by constant infusion)
Number of subjects: 10
Study: 29401210

Group type: EXPERIMENTAL
Intervention: Patients who chose paintings displayed in rooms
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Patients whose paintings were randomly selected
Number of subjects: 186

Group type: COMPARATOR
Intervention: Patients with no paintings
Number of subjects: 186
Study: 27027616

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (N-AC) 70 mg kg(‐1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 24632280

Group type: EXPERIMENTAL
Intervention: FIRM-guided ablation
Number of subjects: 92

Group type: COMPARATOR
Intervention: FIRM-blinded therapy
Number of subjects: 92
Study: 23400715

Group type: EXPERIMENTAL
Intervention: Sifalimumab (0.3, 1.0, 3.0, or 10.0 mg/kg)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Sifalimumab
Number of subjects: 161
Study: 22131734

Group type: EXPERIMENTAL
Intervention: Trayodashanga Kwatha with Madhu (Group A)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pradhamana Nasya with Trikatu + Triphala Churna (Group B)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pradhamana Nasya followed by oral Trayodashanga Kwatha with Madhu (Group C)
Number of subjects: 31
Study: 18616969

Group type: EXPERIMENTAL
Intervention: Antipsychotic drug treatment
Number of subjects: 2463
Study: 16398774

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 900

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 900
Study: 12851520

Group type: EXPERIMENTAL
Intervention: Antihypertensive agents (beta-blocker, non-beta-blocker, or beta-blocker plus non-beta-blocker)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Untreated hypertensive women
Number of subjects: 288

Group type: COMPARATOR
Intervention: Normotensive women
Number of subjects: 288
Study: 11759977

Group type: EXPERIMENTAL
Intervention: ondansetron-dexamethasone-lorazepam
Number of subjects: 30

Group type: COMPARATOR
Intervention: metoclopramide-dexamethasone-lorazepam
Number of subjects: 30
Study: 9231864

Group type: EXPERIMENTAL
Intervention: Opioid drug via patient-controlled analgesia (PCA) systems for 7 days or more
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Summary measure for the simultaneous change in three variables
Number of subjects: 33
Study: 7956549

Group type: EXPERIMENTAL
Intervention: PG05 0.25 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: ONO-802 0.125 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Oxytocin i.v.
Number of subjects: 99
Study: 3310925

Group type: EXPERIMENTAL
Intervention: Nonathymulin 5 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30987424

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Resistance Training (RT)
Number of subjects: 28
Study: 28433814

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 70
Study: 25828385

Group type: EXPERIMENTAL
Intervention: INVOS (a trend monitor using two infrared wavelengths)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: FORE‐SIGHT (a monitor using four wavelengths of laser light to calculate absolute oxygen saturation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Awake volunteers (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Comparison of INVOS with FORE‐SIGHT
Number of subjects: 40
Study: 23362148

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMFs) treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 44
Study: 21286922

Group type: EXPERIMENTAL
Intervention: Hyperglycemic-hyperinsulinemic clamp (HCC)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control
Number of subjects: 7
Study: 19645142

Group type: EXPERIMENTAL
Intervention: Fast track group (FTG)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Non-fast track group (non-FTG)
Number of subjects: 105
Study: 17348883

Group type: EXPERIMENTAL
Intervention: Standard cylindrical implants
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Tapered implants
Number of subjects: 208

Group type: COMPARATOR
Intervention: Both implant designs
Number of subjects: 208
Study: 15513382

Group type: EXPERIMENTAL
Intervention: Biennial Hemoccult‐II test
Number of subjects: 61933

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61933
Study: 11380525

Group type: EXPERIMENTAL
Intervention: Baseline HR dynamics
Number of subjects: 109
Study: 9638698

Group type: EXPERIMENTAL
Intervention: Gow-Gates mandibular block with the new guiding device
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gow-Gates mandibular block without the guiding device (control group)
Number of subjects: 40
Study: 7527229

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia plus epidural anesthesia
Number of subjects: 15

Group type: COMPARATOR
Intervention: Isoflurane anesthesia plus epidural anesthesia
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both sevoflurane and isoflurane
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sevoflurane and isoflurane
Number of subjects: 15
Study: 2592230

Group type: EXPERIMENTAL
Intervention: Screening for symptoms of minor psychiatric disorder at six weeks post partum
Number of subjects: 100
Study: 5109411

Group type: EXPERIMENTAL
Intervention: Intrathecal chemotherapy with methotrexate
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intrathecal chemotherapy with cytosine arabinoside
Number of subjects: 38

Group type: COMPARATOR
Intervention: Prophylactic intrathecal chemotherapy (control group)
Number of subjects: 38
Study: 31740469

Group type: EXPERIMENTAL
Intervention: Community-led interventions through women's self-help group federations
Number of subjects: 6638
Study: 28164731

Group type: EXPERIMENTAL
Intervention: PEC I (consume 50 mL of PEC/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PEC II (consume 100 mL of PEC/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (consume 50 mL of simulated prune drink)
Number of subjects: 60
Study: 25740672

Group type: EXPERIMENTAL
Intervention: Topical timolol 5 mg/mL solution applied twice daily for an average of 4.0 ± 1.1 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combined sequential pulsed dye and Nd:YAG laser treatment for an average of 5.5 ± 0.9 months
Number of subjects: 60
Study: 23942577

Group type: EXPERIMENTAL
Intervention: Preoperative spiritual/religious training intervention (Zikr), 5 sessions of 45 minutes duration
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 70
Study: 21269990

Group type: EXPERIMENTAL
Intervention: Computer-based environment
Number of subjects: 180

Group type: COMPARATOR
Intervention: Paper-based environment
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Adequate literacy
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: TOFHLA score
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Task environment
Number of subjects: 180
Study: 19255380

Group type: EXPERIMENTAL
Intervention: Posttraumatic stress disorder (PTSD)
Number of subjects: 1698

Group type: COMPARATOR
Intervention: Exposure to traumatic events without PTSD
Number of subjects: 1698
Study: 17076630

Group type: EXPERIMENTAL
Intervention: Fixed combination of timolol and dorzolamide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Latanoprost plus timolol
Number of subjects: 16
Study: 15298075

Group type: EXPERIMENTAL
Intervention: Gaboxadol
Number of subjects: 0
Study: 11696618

Group type: EXPERIMENTAL
Intervention: Standard-fractionated radiotherapy (60 Gy/30 fractions/6 weeks) with concurrent cisplatin (80 mg/m² on day 1) and vindesine (3 mg/m² on days 1 and 8 every 4 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Accelerated-hyperfractionated radiotherapy (54 Gy/36 fractions/3.6 weeks) with concurrent cisplatin (80 mg/m² on day 1) and vindesine (3 mg/m² on days 1 and 8 every 4 weeks)
Number of subjects: 21